The role of 15-LOX-1 in colitis and colitis-associated colorectal cancer

Inflammation Research

Volumn 64, Issue 9, 2015, Pages 661-669

  Mao, Fei ^a   Wang, Mei ^a   Wang, Juanjuan ^a   Xu, Wen Rong ^a  

^a JIANGSU UNIVERSITY   (China)

Author keywords

15 LOX 1; Colitis; Colorectal cancer; n 3 Polyunsaturated fatty acids

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONIC ACID; LINOLEIC ACID; LIPID; OMEGA 3 FATTY ACID; UNSATURATED FATTY ACID;

APOPTOSIS; CELL ADHESION; CELL PROLIFERATION; CHRONIC INFLAMMATION; COLITIS; COLITIS ASSOCIATED COLORECTAL CANCER; COLORECTAL CANCER; DISEASE COURSE; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; ANIMAL; COLORECTAL NEOPLASMS; COMPLICATION; METABOLISM;

ANIMALS; ARACHIDONATE 15-LIPOXYGENASE; COLITIS; COLORECTAL NEOPLASMS; FATTY ACIDS, UNSATURATED; HUMANS;

EID: 84939255176     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-015-0852-7     Document Type: Review

References (102)

1. Grechkin A. Recent developments in biochemistry of the plant lipoxygenase pathway. Prog Lipid Res. 1998;37:317–52.
2. Gerwick WH. Structure and biosynthesis of marine algal oxylipins. Biochim Biophys Acta. 1994;1211:243–55.
3. Funk CD. The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim Biophys Acta. 1996;1304:65–84.
4. Yamamoto S, Suzuki H, Ueda N. Arachidonate 12-lipoxygenases. Prog Lipid Res. 1997;36:23–41.
5. Andre E, Hou K. Sur la presence dcune oxydase des lipids ou lipoxydase dans la grain de so ja, glycine so ja life. Comptes Rendus. 1932;194:645–7.
6. Hamberg M, Samuelsson B. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sci USA. 1974;71:3400–4.
7. Brash AR. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem. 1999;274:23679–82.
8. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211–7.
9. Ford AC, Moayyedi P, Hanauer SB. Ulcerative colitis. BMJ. 2013;346:f432.
10. Fürstenberger G, Krieg P, Müller-Decker K, Habenicht AJR. What are cyclooxygenases and lipoxygenases doing in the driver’s seat of carcinogenesis? Int J Cancer. 2006;119:2247–54.
11. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res. 2001;61:6307–12.
12. Moussalli MJ, Yuanging W, Zuo X, Xiu LY, Ignacio IW, Maria GR, Jeffrey SM, Jessica LB, John DM, Reuben L, Shureiqi I. Mechanistic contribution of ubiquitous 15-Lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion. Cancer Prev Res (Phila). 2011;4:1961–72.
13. Schewe T, Halangk W, Hiebsch C, Rapoport S. Degradation of mitochondria by cytosolic factors in reticulocytes. Acta Biologica et Medica Germanica. 1977;36:563–72.
14. Kühn H, Brash AR. Occurrence of lipoxygenase products in membranes of rabbit reticulocytes. Evidence for a role of the reticulocyte lipoxygenase in the maturation of red cells. J Biol Chem. 1990;265:1454–8.
15. Van Leyen K, Duvoisin RM, Engelhardt H, Wiedmann M. A function for lipoxygenase in programmed organelle degradation. Nature. 1998;395:392–5.
16. Grullich C, Duvoisin RM, Wiedmann M, van Leyen K. Inhibition of 15-lipoxygenase leads to delayed organelle degradation in the reticulocyte. FEBS Lett. 2001;489:51–4.
17. Kim KS, Chun HS, Yoon JH, Lee JG, Lee JH, Yoo JB. Expression of 15-lipoxygenase-1 in human nasal epithelium: its implication in mucociliary differentiation. Prostag Leukotr Ess. 2005;73:77–83.
18. Hill EM, Eling T, Nettesheim P. Changes in expression of 15-lipoxygenase and prostaglandin-H synthase during differentiation of human tracheobronchial epithelial cells. Am J Respir Cell Mol Biol. 1998;18:662–9.
19. Choi CK, Sukhthankar M, Kim CH, Lee SH, English A, Kihm KD, Baek SJ. Cell adhesion property affected by cyclooxygenase and lipoxygenase: opto-electric approach. Biochem Bioph Res Co. 2010;391:1385–9.
20. Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, Morris JS, Fan HZ, Fischer SM, Lippman SM. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci USA. 2003;100:9968–73.
21. Chapkin RS, McMurray DN, Lupton JR. Colon cancer, fatty acids and anti-inflammatory compounds. Curr Opin Gastroen. 2007;23:48–54.
22. Brash AR, Boeglin WE, Chang MS. Discovery of a second 15S-lipoxygenase in humans. Proc Natl Acad Sci USA. 1997;94:6148–52.
23. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Ushikubi F, Narumiya S, Sugimura T, Wakabayashi K. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res. 1999;59:5093–6.
24. Oh SF, Pillai PS, Recchiuti A, Yang R, Serhan CN. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest. 2011;121:569–81.
25. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem. 2003;278:14677–87.
26. Merched AJ, Ko K, Gotlinger KH, Serhan CN, Chan L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. The FASEB J. 2008;22:3595–606.
27. Serhan CN. Lipoxins and aspirin-triggered 15-epilipoxins are the first lipid mediators of endogenous antiinflammation and resolution. Prostaglandins Leukot Essent Fatty Acids. 2005;73:141–62.
28. Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammation and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007;25:101–37.
29. Kühn H, O’Donnell VB. Inflammation and immune regulation by 12/15-lipoxygenases. Prog Lipid Res. 2006;45:334–56.
30. Nadel JA, Conrad DJ, Ueki IF, Schuster A, Sigal E. Immunocytochemical localization of arachidonate 15-lipoxygenase in erythrocytes, leukocytes, and airway cells. J Clin Invest. 1991;87:1139–45.
31. MacMillan DK, Hill E, Sala A, Sigal E, Shuman T, Henson PM, Murphy RC. Eosinophil 15-lipoxygenase is a leukotriene A4 synthase. J Biol Chem. 1994;269:26663–8.
32. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, Moos MP, Kaiser B, Cohnert TU, Wahlers T, Zieske A, Plenz G, Robenek H, Salbach P, Kuhn H, Radmark O, Samuelsson B, Habenicht AJ. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA. 2003;100:1238–43.
33. Brinckmann R, Topp MS, Zalan I, Heydeck D, Ludwig P, Kühn H, Berdel WE, Habenicht JR. Regulation of 15-lipoxygenase expression in lung epithelial cells by interleukin-4. Biochem J. 1996;318:305–12.
34. Spanbroek R, Hildner M, Kohler A, Muller A, Zintl F, Kühn H, Rådmark O, Samuelsson B, Habenicht AJ. IL-4 determines eicosanoid formation in dendritic cells by down-regulation of 5-lipoxygenase and up-regulation of 15-lipoxygenase 1 expression. Proc Natl Acad Sci USA. 2001;98:5152–7.
35. Green-Mitchell SM, Tersey SA, Cole BK, Ma K, Kuhn NS, Cunningham TD, Maybee NA, Chakrabarti SK, McDuffie M, Taylor-Fishwick DA, Mirmira RG, Nadler JL, Morris MA. Deletion of 12/15-lipoxygenase alters macrophage and islet function in NOD-Alox15(null) mice, leading to protection against type 1 diabetes development. PLoS One. 2013;8:e56763.
36. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001;2:612–9.
37. Zhao H, Zhang X, Chen X, Li Y, Ke Z, Tang T, Chai H, Guo AM, Chen H, Yang J. Isoliquiritigenin, a flavonoid from licorice, blocks M2 macrophage polarization in colitis-associated tumorigenesis through downregulating PGE2 and IL-6. Toxicol Appl Pharmacol. 2014;279:311–21.
38. Zuo X, Wu Y, Morris JS, Stimmel JB, Leesnitzer LM, Fischer SM, Lippman SM, Shureiqi I. Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene. 2006;25:1225–41.
39. Sasaki T, Fujii K, Yoshida K, Shimura H, Sasahira T, Ohmori H, Kuniyasu H. Peritoneal metastasis inhibition by linoleic acid with activation of PPARγ in human gastrointestinal cancer cells. Virchows Arch. 2006;448:422–7.
40. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-[gamma] is a negative regulator of macrophage activation. Nature. 1998;391:79–82.
41. Zuo X, Peng Z, Wu Y, Moussalli MJ, Yang XL, Wang Y, Parker-Thornburg J, Morris JS, Broaddus RR, Fischer SM, Shureiqi I. Effects of gut-targeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice. J Natl Cancer Inst. 2012;104:709–16.
42. Shankaranarayanan P, Chaitidis P, Kühn H, Nigam S. Acetylation by histone acetyltransferase CREB-binding protein/p300 of STAT6 is required for transcriptional activation of the 15-lipoxygenase-1 gene. J Biol Chem. 2001;276:42753–60.
43. Conrad DJ, Lu M. Regulation of human 12/15-lipoxygenase by Stat6-dependent transcription. Am J Respir Cell Mol Biol. 2000;22:226–34.
44. Liu C, Xu D, Sjöberg J, Björkholm M, Claesson HE. Transcriptional regulation of 15-lipoxygenase expression by promoter methylation. Exp Cell Res. 2004;297:61–7.
45. Liu C, Xu D, Han H, Fan Y, Schain F, Xu Z, Claesson HE, Björkholm M, Sjöberg J. Transcriptional regulation of 15-lipoxygenase expression by histone h3 lysine 4 methylation/demethylation. PLoS One. 2012;7:e52703.
46. Hsi LC, Kundu S, Palomo J, Xu B, Ficco R, Vogelbaum MA, Cathcart MK. Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous signaling. Mol Cancer Ther. 2011;10:1149–60.
47. Roy B, Bhattacharjee A, Xu B, Ford D, Maizel AL, Cathcart MK. IL-13 signal transduction in human monocytes: phosphorylation of receptor components, association with Jaks, and phosphorylation/activation of Stats. J Leukoc Biol. 2002;72:580–9.
48. Roy B, Cathcart MK. Induction of 15-lipoxygenase expression by IL-13 requires tyrosine phosphorylation of Jak2 and Tyk2 in human monocytes. J Biol Chem. 1998;273:32023–9.
49. Lee YW, Kühn H, Kaiser S, Hennig B, Daugherty A, Toborek M. Interleukin 4 induces transcription of the 15-lipoxygenase I gene in human endothelial cells. J Lipid Res. 2001;42:783–91.
50. Munger KA, Montero A, Fukunaga M, Uda S, Yura T, Imai E, Kaneda Y, Valdivielso JM, Badr KF. Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc Natl Acad Sci USA. 1999;96:13375–80.
51. Mangino MJ, Brounts L, Harms B, Heise C. Lipoxin biosynthesis in inflammatory bowel disease. Prostag Oth Lipid M. 2006;79:84–92.
52. Il Lee S, Zuo X, Shureiqi I. 15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in? Cancer Metastasis Rev. 2011;30:481–91.
53. Hudert CA, Weylandt KH, Lu Y, Wang J, Hong S, Dignass A, Serhan CN, Kang JX. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. P Natl Acad Sci USA. 2006;103:11276–81.
54. Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res. 2002;62:403–8.
55. Spite M, Norling L, Summers L, Yang R, Cooper D, Petasis NA, Flower RJ, Perretti M, Serhan CN. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature. 2009;461:1287–91.
56. Ma J, Chen T, Mandelin J, Ceponis A, Miller NE, Hukkanen M, Ma GF, Konttinen YT. Regulation of macrophage activation. Cell Mol Life Sci. 2003;60:2334–46.
57. Serhan CN, Jain A, Marleau S, Clish C, Kantarci A, Behbehani B, Colgan SP, Stahl GL, Merched A, Petasis NA, Chan L, Van Dyke TE. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol. 2003;171:6856–65.
58. Saraiva TD, Morais K, Pereira VB, de Azevedo M, Rocha CS, Prosperi CC, Gomes-Santos AC, Bermudez-Humaran L, Faria AM, Blottiere HM, Langella P, Miyoshi A, de LeBlanc Ade M, LeBlanc JG, Azevedo V. Milk fermented with a 15-lipoxygenase-1-producing lactococcus lactis alleviates symptoms of colitis in a murine model. Curr Pharm Biotechnol. 2015;16:424–9.
59. Reynier M, Sari H, d’Anglebermes M, Kye EA, Pasero L. Differences in lipid characteristics of undifferentiated and enterocytic-differentiated HT29 human colonic cells. Cancer Res. 1991;51:1270–7.
60. Hendrickse CW, Kelly RW, Radley S, Donovan IA, Keighley MR, Neoptolemos JP. Lipid peroxidation and prostaglandins in colorectal cancer. Br J Surg. 1994;81:1219–23.
61. Baer AN, Costello PB, Green FA. In vivo activation of an omega-6 oxygenase in human skin. Biochem Biophys Res Commun. 1991;180:98–104.
62. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, Oshima M, Taketo MM. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med. 2001;7:1048–51.
63. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, Blumberg RS, Serhan CN. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci USA. 2005;102:7671–6.
64. Bento AF, Claudio RF, Dutra RC, Marcon R, Calixto JB. Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J Immunol. 2011;187:1957–69.
65. Das UN, Huang YS, Begin ME, Ells G, Horrobin DF. Uptake and distribution of cis-unsaturated fatty acids and their effect on free radical generation in normal and tumor cells in vitro. Free Radic Biol Med. 1987;3:9–14.
66. Tjonahen E, Oh SF, Siegelman J, Elangovan S, Percarpio KB, Hong S, Arita M, Serhan CN. Resolvin E2: indentification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem Biol. 2006;13:1193–202.
67. Cho J, Chi SG, Chun HS. Oral administration of docosahexaenoic acid attenuates colitis induced dextran sulfate sodium in mice. Mol Nutr Food Res. 2011;55:239–46.
68. Oh SF, Dona M, Fredman G, Krishnamoorthy S, Irimia D, Serhan CN. Resolvin E2 formation and impact in inflammation-resolution. J Immunol. 2012;188:4527–34.
69. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin d1 activate inflammation-resolution programs. Nature. 2007;447:869–74.
70. Serhan CN, Chiang N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol. 2008;153(suppl 1):S200–15.
71. Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, Petasis NA, Levy BD, Serhan CN, Van Dyke TE. RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. FASEB J. 2006;20:401–3.
72. Vandivier RW, Henson PM, Douglas IS. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest. 2006;129:1673–82.
73. Calandria JM, Marcheselli VL, Mukherjee PK, Uddin J, Winkler JW, Petasis NA, Bazan NG. Selective survival rescue in 15-lipoxygenase-1-deficient retinal pigment epithelial cells by the novel docosahexaenoic acid-derived mediator, neuroprotectin D1. J Biol Chem. 2009;284:17877–82.
74. Xu MX, Tan BC, Zhuo W, Wei T, Lai WH, Tan JW, Dong JH. Resolvin D1, an endogenous lipid mediator for inactivation of inflammation-related signaling pathway in microglial cells, prevents lipopolysaccharide-induced inflammatory responses. CNS Neurosci Ther. 2013;19:235–43.
75. Liao Z, Dong J, Wu W, Yang T, Wang T, Guo L, Chen L, Xu D, Wen F. Resolvin D1 attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process involving the PPARy/NF-kB pathway. Resp Res. 2012;13:110.
76. Itoh T, Fairall L, Amin K, Inaba Y, Szanto A, Balint BL, Nagy L, Yamamoto K, Schwabe JW. Structural basis for the activation of PPAR gamma by oxidized fatty acids. Nat Struct Mol Biol. 2008;15:924–31.
77. Maddox JF, Hachicha M, Takano T, Petasis NA, Fokin VV, Serhan CN. Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein linked lipoxin A4 receptor. J Biol Chem. 1997;272:6972–8.
78. Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, Petasis NA, Serhan CN. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. PNAS. 2010;107:1660–5.
79. Krishnamoorthy S, Recchiuti A, Chiang N, Fredman G, Serhan CN. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. AJP. 2012;180:2018–27.
80. Bohr S, Patel S, Sarin D, Irimia D, Yarmush M, Berthiaume F. Resolvin D2 prevents secondary thrombosis and necrosis in a mouse burn wound model. Wound Rep Reg. 2013;21:35–43.
81. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediator. Nat Rev Immunol. 2008;8:349–61.
82. Sans M, Panes J, Ardite E, Elizalde JI, Arce Y, Elena M, Palacin A, Fernandez-Checa JC, Anderson DC, Lobb R, Pique JM. VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis. Gastroenterology. 1999;116:874–83.
83. Soriano A, Salas A, Salas A, Sans M, Gironella M, Elena M, Anderson DC, Pique JM, Panes J. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest. 2000;80:1541–51.
84. Bazan NG, Calandria JM, Serhan CN. Rescue and repair during photoreceptor cell renewal mediated by docosahexaenoic acid-derived neuroprotectin D1. J Lipid Res. 2010;51:2018–31.
85. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA. 2004;101:8491–6.
86. Gerrits MM, Chen M, Theeuwes M, van Dekken H, Sikkema M, Steyerberg EW, Lingsma HF, Siersema PD, Xia B, Kusters JG, van der Woude CJ, Kuipers EJ. Biomarker-based prediction of inflammatory bowel disease-related colorectal cancer: a case-control study. Cell Oncol (Dordr). 2011;34:107–17.
87. Yang X, Zhang F, Wang Y, Cai M, Wang Q, Guo Q, Li Z, Hu R. Oroxylin A inhibits colitis-associated carcinogenesis through modulating the IL-6/STAT3 signaling pathway. Inflamm Bowel Dis. 2013;19:1990–2000.
88. Marnett IJ, De Bois RN. COX-2: target for colon cancer prevention. Annu Rev Pharmacol Toxicol. 2002;42:55–80.
89. Shureiqi I, Chen D, Day RS, Zuo X, Hochman FL, Ross WA, Cole RA, Moy O, Morris JS, Xiao L, Newman RA, Yang P, Lippman SM. Profiling lipoxygenase metabolism in specific steps of colorectal tumorigenesis. Cancer Prev Res (Philadelphia, Pa.). 2010;3:829–38.
90. Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease—Enhanced production during active disease. Gut. 1990;31:686–9.
91. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005;41:2502–12.
92. Mao F, Xu M, Zuo X, Yu J, Xu W, Moussalli MJ, Elias E, Li HS, Watowich SS. Shureiqi I 15-Lipoxygenase-1 suppression of colitis-associated colon cancer through inhibition of the IL-6/STAT3 signaling pathway. FASEB J. 2015;29:2359–70.
93. Dijkstra G, Moshage H, Jansen PL. Blockade of NF-kappaB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease? Scand J Gastroenterol Suppl. 2002;37:37–41.
94. Zuo X, Shureiqi I. Eicosanoid profiling in colon cancer: emergence of a pattern. Prostag oth Lipid M. 2013;104–105:139–43.
95. Viennois E, Chen F, Merlin D. NF-kB pathway in colitis-associated cancers. Transl Gastrointest Cancer. 2013;2:21–9.
96. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest. 1999;104:383–9.
97. Tanaka T, Kohno H, Yoshitani S, Takashima S, Okumura A, Murakami A, Hosokawa M. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res. 2001;61:2424–8.
98. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol. 2003;171:6164–72.
99. Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, Tani K, Kobayashi M, Maruyama T, Kobayashi K, Ohuchida S, Sugimoto Y, Narumiya S, Sugimura T, Wakabayashi K. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 2002;62:28–32.
100. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, Pretlow TP, Newman RA, Willis J, Dawson D, Markowitz SD. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA. 2006;103:12098–102.
101. Brenner RR. Nutritional and hormonal factors influencing desaturation of essential fatty acids. Prog Lipid Res. 1981;20:41–7.
102. Huang YS, Liu JW, Koba K, Anderson SN. N-3 and n-6 fatty acid metabolism in undifferentiated and differentiated human intestine cell line (Caco-2). Mol Cell Biochem. 1995;151:121–30.